Structure Therapeutics Inc. (GPCR)
Pre-market:
| Previous close | 51.64 |
| Open | 52.14 |
| Bid | 48.06 x 800 |
| Ask | 48.38 x 500 |
| Day's range | 46.60 - 52.14 |
| 52-week range | 25.57 - 75.02 |
| Volume | |
| Avg. volume | 954,438 |
| Market cap | 2.748B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.25 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 85.11 |
ZacksStructure Therapeutics (GPCR) Rallying on Obesity Drug Data
Structure Therapeutics (GPCR) stock sees an upside on positive top-line data from a phase IIa obesity study as well as a capsule-to-tablet PK study on its obesity candidate, GSBR-1290.
GlobeNewswireStructure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
SAN FRANCISCO, June 07, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced the closing of its previously announced upsized underwritten public offering of 10,427,017 American depositary shares (ADSs), each representing three ordinary shares, including the full exercise of the underwriters’ option to purchase up to 1,360,
- GlobeNewswire
Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering
SAN FRANCISCO, June 05, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced the pricing of its upsized underwritten public offering of 9,066,972 American depositary shares (ADSs), each representing three ordinary shares, at a public offering price of $52.50 per ADS. The aggregate gross proceeds to Structure Therapeutics f
